The goal of this clinical trial is to investigate whether methylene blue injection can safely and effectively improve the survival rate of patients with severe septic shock, shorten the duration of norepinephrine use, reduce the dosage of vasopressors, promptly correct hemodynamics, and improve tissue perfusion and organ function impairment.

Start Date20 Jun 2024

Sponsor / Collaborator

The First Affiliated Hospital, Zhejiang University School of Medicine

[+3]

ChiCTR2300078223 / RecruitingNot ApplicableIIT

Baseline levels and influencing factors of TMAO, TMAVA, and precursor TML in healthy adults

Start Date01 Dec 2023

Sponsor / Collaborator

Second People's Hospital of Nanning

ChiCTR2300077759 / RecruitingEarly Phase 1IIT

A single-arm clinical study of PD-1Ab21-CD19CAR-T cells in the treatment of CD19-positive hematological malignancies

Start Date15 May 2023

Sponsor / Collaborator

Second People's Hospital of Nanning

100 Clinical Results associated with Second People's Hospital of Nanning

0 Patents (Medical) associated with Second People's Hospital of Nanning

457

Literatures (Medical) associated with Second People's Hospital of Nanning

01 Dec 2024·International Immunopharmacology

Unlocking Immunity: Innovative prostate cancer vaccine strategies

Review

Author: Zhou, Xiaohui ; Zhou, Zhenxian ; Gu, Qiannan ; Zhou, Zhenxian. ; Wang, Ne. ; Gu, Qiannan. ; Qi, Anning. ; Zhou, Xiaohui. ; Qi, Anning ; Wang, Ne

OBJECTIVEProstate Cancer (PCa) is a leading cause of cancer-related mortality in men, especially in Western societies. The objective of this research is to address the unmet need for effective treatments in advanced or recurrent PCa, where current strategies fall short of offering a cure. The focus is on leveraging immunotherapy and cancer vaccines to target the tumor's unique immunological microenvironment.MAIN RESULTSDespite immunotherapy's success in other cancers, its effectiveness in PCa has been limited by the tumor's immunosuppressive characteristics. However, cancer vaccines that engage Tumor-Specific Antigens (TSA) and Tumor-Associated Antigens (TAA) have emerged as a promising approach. Preclinical and clinical investigations of Dendritic Cell (DC) vaccines, DNA vaccines, mRNA vaccines, peptide vaccines, and viral vectors have shown their potential to elicit anti-tumor immune responses. The exploration of combination therapies with immune checkpoint inhibitors and the advent of novel adjuvants and oral microparticle vaccines present innovative strategies to improve efficacy and compliance.CONCLUSIONThe development of cancer vaccines for PCa holds significant potential. Future directions include optimizing vaccine design, refining combination therapy strategies, and creating patient-friendly administration methods. The integration of interdisciplinary knowledge and innovative clinical trial designs is essential for advancing personalized and precision immunotherapy for PCa.

01 Dec 2024·Journal of Radiation Research and Applied Sciences

Protective effects of extracts of forsythia suspensa and chrysanthemum on alcoholic hypertension rats based on tissue pathological slice image analysis

Author: Shibo, Zhao ; Lu, Lu ; Zhonggang, Wu ; Yeminxiao, Zeng ; Hanjun, Ma ; Yixin, Zhang

To explore the effects of Forsythia suspensa and Chrysanthemum indicum extracts on blood pressure as well as hepatic and renal functions of hypertensive rats and to optimize the most beneficial combination of the two herbs to achieve this goal.After hypertension was observed, rats were administrated with extracts of F. suspensa and C. indicum by gastric perfusions at doses of 20 mL/kg, for fourteen days.On the fourteenth day, rats were fasted for 12 h and then blood was collected from the eyeballs for serum measurement of alanine transaminase, aspartate aminotransferase, alk. phosphatase, albumin, total cholesterol, triglycerides, very low d. lipoprotein, sodium, potassium and creatinine.Hepatic and renal tissue were harvested and processed into paraffin blocks for observation.F. suspensa and C. indicum at a ratio of 2:1 was the most effective with respect to liver repair in the hypertensive rats (p < 0.05).Both plant extracts decreased serum lipids and creatinine with the ratio of 2:1 of the two extracts being the most beneficial (p < 0.05).A synergistic effect on decreasing blood pressure and protection of the liver was observed in the hypertensive rats when extracts of F. suspensa and C. indicum were administered in combination.F. suspensa and C. indicum at a ratio of 2:1 was the most effective.

01 Nov 2024·Toxicology Letters

Flavopiridol inhibits oocyte maturation, reduces oocyte quality and blocks cumulus cell function

Article

Author: Xu, Chang-Long ; Yi, Li-Tao ; Li, Xiao-Zhen ; Yin, Shen ; Sun, Qing-Yuan

Flavopiridol (FP) is a plant-derived flavonoidis and used to treat cancers, fungal infections and inflammation-related diseases. However, it is not clear whether it has side effects on the female reproductive system. In this study, we aimed to investigate the toxic effects and potential underlying mechanisms of FP on oocyte maturation and cumulus cell expansion in mice. Cumulus-oocyte complexes (COCs) were cultured in vitro with FP of gradient concentration (50-1000nM), according to the plasma concentration of FP in the clinical trial. The maturation rate and cumulus expansion index of oocytes were counted and studied by immunofluorescence staining, qRT-PCR, oocyte chromosome preparation and so on. The results showed that the FP-exposed COCs inhibited the oocyte maturation and cumulus cell expansion, leading to cell apoptosis in a dose dependent way. Oocytes exposed to 500nM FP showed abnormalities in the spindle structure and chromosome arrangement, ultimately leading to the oocyte maturation arrest and aneuploidy. This may be due to the excessive oxidative stress caused by mitochondrial membrane potential damage and mislocalization. Therefore, when FP is used for cancer treatment, its side effects on the female reproductive system should be seriously considered.

100 Deals associated with Second People's Hospital of Nanning

100 Translational Medicine associated with Second People's Hospital of Nanning

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 14 Nov 2024

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Second People's Hospital of Nanning

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 14 Nov 2024

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing